ANDA Litigation Soars In 2014-2015; Patent Office Petitions Also Jump
This article was originally published in The Pink Sheet Daily
Executive Summary
Purdue's OxyContin and Amarin's Vascepa lead the list of targets as an increasing number of generic firms take up litigation.